Aminohexane diphosphonate in the treatment of Paget's disease of bone.
We studied the effects of the intravenous or oral administration of aminohexane diphosphonate (AHDP) in 42 patients with active Paget's disease of bone. Treatment of mouth (400 mg daily for 1 month) or intravenously (25 mg or 50 mg daily for 5 days) induced marked suppression of biochemical indices of disease activity. Urinary excretion of hydroxyproline fell to 39 and 42% of pretreatment values (oral and IV treatments respectively), and was followed by a similar decrease in the serum activity of alkaline phosphatase. In both groups of patients, disease activity remained suppressed for the 6 months of followup, and pain improved in 34 out of 37 patients who had bone pain attributed to Paget's disease. Both biopsies indicated that osteoblast and osteoclast numbers decreased with no adverse effects on mineralization. Neither regime was associated with significant side effects. We conclude that short courses of AHDP provide a promising treatment for the long-term control of Paget's disease.
Atkins
R M
RM
Department of Human Metabolism & Clinical Biochemistry, University of Sheffield Medical School, UK.
Yates
A J
AJ
Gray
R E
RE
Urwin
G H
GH
Hamdy
N A
NA
Beneton
M N
MN
Rosini
S
S
Kanis
J A
JA
D000284:Administration, Oral; D000469:Alkaline Phosphatase / Q000097:blood; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D007275:Injections, Intravenous; D010001:Osteitis Deformans / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D013997:Time Factors
D004164:Diphosphonates; D000469:Alkaline Phosphatase; D006909:Hydroxyproline